VSV-EBOVAC Consortium reports that a dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa
First Innovative Medicines Initiative Ebola projects get underway
- Innovative Medicines Initiative (IMI) is launching first eight projects on Ebola, covering vaccine development and manufacture, vaccine uptake, and diagnostics.
- Projects are part of the wider IMI Ebola+ programme, which is designed to contribute to efforts to tackle a broad range of major challenges in Ebola research while complementing work supported by other funding bodies.
- Total budget of the eight projects launched: €215 million. Support comes from the EU's research and innovation programme Horizon 2020 and the EFPIA partners in the projects.